![]() |
||||||||||||||
![]() |
![]() |
|||||||||||||
![]() |
![]() |
|||||||||||||
![]() |
![]() |
![]() |
![]() |
|||||||||||
![]() |
![]() |
|||||||||||||
![]() |
![]() |
|||||||||||||
VOLUME 4, NUMBER 28 |
November 14, 2014 |
![]() |
||||||||||||
![]() |
![]() |
![]() |
![]() |
|||||||||||
![]() |
THERE ARE FOUR PRIMARY PHARMACOLOGICAL TREATMENT OPTIONS FOR PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION (AMD)MACUGEN (PEGAPTANIB, VALEANT PHARMACEUTICALS), LUCENTIS (RANIBIZUMAB, GENENTECH/ROCHE), AVASTIN (BEVACIZUMAB, GENENTECH/ROCHE) AND EYLEA (AFLIBERCEPT, REGENERON). WHILE ALL FOUR AGENTS INHIBIT VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) BINDING AND ACTIVATION, UNDERSTANDING THEIR SUBTLE DIFFERENCES WILL ALLOW YOU TO MORE EFFECTIVELY EDUCATE YOUR PATIENTS AND WILL HELP YOU DETERMINE WHEN A REFERRAL IS WARRANTED. |
![]() |
![]() |
![]() |
||||||||||
In 2004, Macugen became the first anti-VEGF agent to receive FDA approval for the treatment of neovascular AMD.
The drug is delivered via
intravitreal injection,
and is specifically indicated for dosing every six weeks. While Macugen is not currently FDA approved for
the treatment of diabetic macular edema, researchers have documented significant visual improvement in
affected patients following treatment.¹
|
![]() |
|||||||||||||
![]() |
![]() |
|||||||||||||
![]() |
"Every man should pull a boat over a mountain once in his life."
|
![]() |
||||||||||||
![]() |
![]() |
|||||||||||||
![]() |
![]() |
|||||||||||||
![]() |
![]() |
![]() |
![]() |
|||||||||||
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Review of Optometry® is published by the Review Group, a Division of Jobson Medical Information LLC (JMI), 11 Campus Boulevard, Newtown Square, PA 19073. To subscribe to other JMI newsletters or to manage your subscription, click here. To change your email address, reply to this email. Write "change of address" in the subject line. Make sure to provide us with your old and new address. To ensure delivery, please be sure to add revoptom@lists.jobsonmail.com to your address book or safe senders list. Click here if you do not want to receive future emails from Review of Optometry. |